A Study Comparing the Effects and Safety of Dulaglutide With Glimepiride in Type 2 Diabetes Mellitus
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to examine if once-weekly dulaglutide is efficient and safe
compared to glimepiride in participants with type 2 diabetes mellitus who have inadequate
glycemic control with oral antihyperglycemic medication (OAM) or are OAM-naïve.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Dulaglutide Glimepiride Immunoglobulin Fc Fragments